Cardiotoxicity Beyond Cardiomyocytes—Focus on the Role of Cardiac Fibroblasts and Endothelial Cells
Heart, Lung and Circulation · 2025-06 · 34 (6) · 606-612
DOI: 10.1016/j.hlc.2024.11.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart, Lung and Circulation, 2025-06. Verfasst von Ymke Appels und 5 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus Medical Center, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Fibroblasts, Myocytes, Cardiac, Cardiotoxicity, Endothelial Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Heart Foundation, Horizon 2020, European Research Council.
Abstract (Originalsprache)
INTRODUCTION: Anti-cancer treatments frequently have serious adverse effects on the cardiovascular system. Understanding the mechanisms underlying these cancer therapy-related cardiovascular toxicities is essential for their prevention and potential treatment. While research often centres on cardiomyocyte damage as the primary cause of cardiac injury, the roles of cardiac fibroblasts and endothelial cells are often neglected. In this study, we aimed to investigate the direct toxicity in cardiac fibroblast and endothelial cells of 35 FDA-approved anti-cancer drugs, of which the effects previously only had been explored in cardiomyocytes. METHODS AND RESULTS: Metabolic cell viability in cardiac fibroblasts and endothelial cells was first determined using the CellTiter-Glo luminescence assay. If metabolic cell viability was reduced, lactate dehydrogenase was measured in the supernatant to assess cytotoxicity. Interestingly, certain anti-cancer treatments were able to increase metabolic cell viability. For these drugs, gene expression analysis assessing for myofibroblast differentiation and endothelial-to-mesenchymal transition was performed. CONCLUSION: Our study demonstrates that anti-cancer therapies indeed exhibited different toxicity profiles in cardiac fibroblasts and endothelial cells compared to cardiomyocytes and triggers specific pathophysiological transformations in response to anti-cancer drug exposure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erasmus Medical Center, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, The Netherlands.
- Department of Outpatient Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.
- Erasmus Medical Center, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, The Netherlands. Electronic address: w.meijers@erasmusmc.nl.
Förderung
- Netherlands Heart Foundation
- Horizon 2020
- European Research Council
- Netherlands Organisation for Health Research and Development
- HORIZON EUROPE European Research Council
Zitieren
APA
Appels, Y., Yousif, L. I., Pieters, C. S., de Boer, R. A., Aboumsallem, J. P., & Meijers, W. C. (2025). Cardiotoxicity Beyond Cardiomyocytes—Focus on the Role of Cardiac Fibroblasts and Endothelial Cells. Heart, Lung and Circulation, 34(6), 606-612. https://doi.org/10.1016/j.hlc.2024.11.010
Vancouver
Appels Y, Yousif LI, Pieters CS, de Boer RA, Aboumsallem JP, Meijers WC. Cardiotoxicity Beyond Cardiomyocytes—Focus on the Role of Cardiac Fibroblasts and Endothelial Cells. Heart, Lung and Circulation. 2025;34(6):606-612. doi:10.1016/j.hlc.2024.11.010
BibTeX
@article{Appels2025,
author = {Appels, Ymke and Yousif, Laura I and Pieters, Charlotte S and de Boer, Rudolf A and Aboumsallem, Joseph Pierre and Meijers, Wouter C},
title = {Cardiotoxicity Beyond Cardiomyocytes—Focus on the Role of Cardiac Fibroblasts and Endothelial Cells},
journal = {Heart, Lung and Circulation},
year = {2025},
volume = {34},
number = {6},
pages = {606--612},
doi = {10.1016/j.hlc.2024.11.010}
}
EUVIMED